6 recruiting, 2 active not recruiting, 1 not yet recruiting. 6 Phase 2, 5 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 4, Active not recruiting 2 |
| Phase 1 | 5 | Recruiting 3, Active not recruiting 1, Not yet recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Liping Dou: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia SL1CC Injection - Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | Liping Dou | 12 | 2026-10-01 | 2026-10-02 |
| Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, Chidamide, and G-CSF - R/R AML | Phase 2 | Active not recruiting | Liping Dou | 32 | 2026-07-30 | 2026-10-15 |
| In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms In vivo BCMA/GPRC5D Tandem Dual CAR-T cell - Plasma Cell Neoplasms | Early Phase 1 | Recruiting | Liping Dou | 18 | 2026-05-09 | 2026-10-02 |
| CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy CD22/CD19 CAR-T cell immunotherapy - Lymphoma | Phase 2 | Recruiting | Liping Dou | 30 | 2026-04-01 | 2026-08-21 |
| Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Liping Dou | 20 | 2026-01-01 | 2026-06-15 |
| CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma CD22/CD19 CAR-T cell immunotherapy - Lymphoma | Phase 2 | Recruiting | Liping Dou | 20 | 2026-01-01 | 2026-05-14 |
| Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Liping Dou | 30 | 2026-01-01 | 2026-06-25 |
| A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT Azacitidine (AZA) Days 1 - 5, Selinexor - Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome) | Phase 1 / Phase 2 | Active not recruiting | Liping Dou | 58 | 2025-05-01 | 2026-08-21 |
| Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL Blinatumomab Injection, Donor Lymphocyte Infusion (DLI) - ALL (Acute B-Lymphoblastic Leukemia) | Phase 1 | Recruiting | Liping Dou | 60 | 2024-12-01 | 2026-07-01 |
Burkitt Lymphoma (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Cytokine Release Syndrome (1) · Neoplasm, Residual (1) · Neoplasms, Plasma Cell (1) · Recurrence (1)
Azacitidine (2) · Cytarabine (1) · Granulocyte Colony-Stimulating Factor (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · blinatumomab (1) · selinexor (1)
China (9)